Slide 1NOAC but NICE Conference 16 th July 2013 Slide 2 Stroke Prevention in Atrial Fibrillation. NICE, NOACS and the future Dr John Duffy Stroke Consultant LTC Clinical…

1. Best practice in asymptomaticcarotid stenosis Dr. Pascual Lozano Vilardell Angiología y Cirugía Vascular 2. BEST PRACTICE FOR ASYMPTOMATIC CAROTID STENOSISClinical trials30…

1. Lipid lowering therapy in CKDWhat is the evidence? Conall O’ Seaghdha Renal Meeting Royal North Shore Hospital 29/08/07 2. Case for Discussion 72 male type II DM ESKD…

Lipid disorder 脂蛋白之測量 需禁食12h Lipoprotein: = Lipids (cholesteryl esters + TG) + phospholipids + proteins 包括: chylomicrons, VLDL, IDL, LDL, HDL, Lp(a)…

DIABETES COMO FACTOR DE RIESGO CARDIOVASCULAR DR. LEOCADIO G. MUÑOZ BELTRAN Normal Arterial Wall Risk Factors for Cardiovascular Disease Modifiable Smoking Dyslipidaemia…

Slide 1 Bureaucratic obstacles to clinical trials: in the public interest? Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological…

Slide 1 The Importance of Potential Statin in High Risk Patient Masrul Syafri Bagian Kardiologi & Kedokteran Vaskular FKUA/RS M Djamil Padang CRE/006/FEB14-FEB15/BR Slide…

Slide 1 Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK Slide 2 HPS: Eligibility criteria Increased…

Slide 1 Maj Gen Farooq Ahmad Khan HI(M) MBBS, MCPS, Dip Endocrinol (Lond), FCPS, FRCP (Ireland), FRC Path (UK), PhD (Lond) Professor of Pathology Armed Forces Institute of…

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage on behalf of the…